Lymph Nodes Overlooked in Ovarian Cancer Patients

Publication
Article
Oncology Live®March 2011
Volume 12
Issue 3

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

Female Lymph Nodes

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes, according to a study by UC Davis Cancer Center and California Cancer Registry researchers. More than a quarter of those cancer patients do not receive the biopsies that have been shown to improve survival rates, the study results found.

Particularly surprising was the disparity in treatment, according to senior study author Gary S. Leiserowitz, MD, chief of Gynecologic Oncology at UC Davis, Sacramento, California. Gynecologic oncologists were 6.5 times more likely to perform lymph node biopsies than other surgical specialists were and nearly 4 times more likely to carry out all recommended staging biopsies.

“The one message is that it would be to a patient’s advantage to see someone in gynecologic oncology who would be more likely to adhere to the staging guidelines,” he said.

Those published guidelines have been in place for decades, said Leiserowitz. In some ways, he said, the study results are a wakeup call. He said there might be a change in the practice pattern with oncologists either adhering to the guidelines or referring their ovarian cancer patients to those proficient in the procedures.

The study, coordinated by lead author Rosemary Cress, DrPH, an epidemiologist and the research program director at the California Cancer Registry, focused on 721 patients in California and New York. Cress identified patients with early-stage epithelial ovarian cancer between 1998 and 2000.

“This should raise the awareness among physicians that it’s really important to do lymph node biopsies in these patients,” said Cress.

Related Videos
Michael Richardson, MD
Gottfried Konecny, MD
Gottfried E. Konecny, MD, lead clinician, gynecologic oncology, Department of Medicine, the University of California, Los Angeles
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania